Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017, Article ID 3510984, 6 pages
https://doi.org/10.1155/2017/3510984
Research Article

A Novel Panel of Serum Biomarkers for MPM Diagnosis

1Operative Unit of Occupational and Environmental Medicine, University Hospital of Pisa, Pisa, Italy
2Department of Translational Research and of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
3Department of Biology, University of Pisa, Pisa, Italy
4Department of Pharmacy, University of Pisa, Pisa, Italy
5Department of Medical Sciences, University of Trieste, Trieste, Italy

Correspondence should be addressed to A. Bonotti; ti.oohay@ittonoba

Received 5 October 2016; Revised 7 February 2017; Accepted 9 February 2017; Published 28 February 2017

Academic Editor: Marco E. M. Peluso

Copyright © 2017 A. Bonotti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Peto, A. Decarli, C. La Vecchia, F. Levi, and E. Negri, “The European mesothelioma epidemic,” British Journal of Cancer, vol. 79, no. 3-4, pp. 666–672, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. V. W. Rusch, D. Giroux, C. Kennedy et al., “Initial analysis of the international association for the study of lung cancer mesothelioma database,” Journal of Thoracic Oncology, vol. 7, no. 11, pp. 1631–1639, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Zellos and D. C. Christiani, “Epidemiology, biologic behavior, and natural history of mesothelioma,” Thoracic Surgery Clinics, vol. 14, no. 4, pp. 469–477, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. B. W. S. Robinson, J. Creaney, R. Lake et al., “Soluble mesothelin-related protein—a blood test for mesothelioma,” Lung Cancer, vol. 49, no. 1, pp. S109–S111, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Hollevoet, J. B. Reitsma, J. Creaney et al., “Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis,” Journal of Clinical Oncology, vol. 30, no. 13, pp. 1541–1549, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Grigoriu, C. Grigoriu, B. Chahine, T. Gey, and A. Scherpereel, “Clinical utility of diagnostic markers for malignant pleural mesothelioma,” Monaldi Archives for Chest Disease, vol. 71, no. 1, 2009. View at Publisher · View at Google Scholar
  7. E.-K. Park, P. S. Thomas, A. R. Johnson, and D. H. Yates, “Osteopontin levels in an asbestos-exposed population,” Clinical Cancer Research, vol. 15, no. 4, pp. 1362–1366, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Cristaudo, A. Bonotti, S. Simonini, R. Bruno, and R. Foddis, “Soluble markers for diagnosis of malignant pleural mesothelioma,” Biomarkers in Medicine, vol. 5, no. 2, pp. 261–273, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. O. Melaiu, A. Cristaudo, E. Melissari et al., “A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma,” Mutation Research/Reviews in Mutation Research, vol. 750, no. 2, pp. 132–140, 2012. View at Publisher · View at Google Scholar
  10. L. Giusti, Y. Da Valle, A. Bonotti et al., “Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament-related proteins,” Proteomics - Clinical Applications, vol. 8, no. 3-4, pp. 258–268, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. H. L. Beyer, R. D. Geschwindt, C. L. Glover et al., “MESOMARK™: a potential test for malignant pleural mesothelioma,” Clinical Chemistry, vol. 53, no. 4, pp. 666–672, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. H. I. Pass, “Biomarkers and prognostic factors for mesothelioma,” Annals of Cardiothoracic Surgery, vol. 1, no. 4, pp. 449–456, 2012. View at Google Scholar
  13. K. Hollevoet, K. Nackaerts, R. Gosselin et al., “Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma,” Journal of Thoracic Oncology, vol. 6, no. 11, pp. 1930–1937, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Cristaudo, A. Bonotti, S. Simonini et al., “Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma,” Journal of Thoracic Oncology, vol. 6, no. 9, pp. 1587–1593, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Muley, H. Dienemann, F. J. F. Herth, M. Thomas, M. Meister, and J. Schneider, “Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer,” Journal of Thoracic Oncology, vol. 8, no. 7, pp. 947–951, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Santarelli, S. Staffolani, E. Strafella et al., “Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma,” Lung Cancer, vol. 90, no. 3, pp. 457–464, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Fukuoka, “Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma,” Molecular and Clinical Oncology, vol. 1, no. 6, pp. 942–948, 2013. View at Publisher · View at Google Scholar